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Abstract: BACKGROUND: Stem cell-enriched fat grafting has been proposed as a potential therapy
for reconstructive, restorative, or enhancement-related procedures of the breast. Its role in postonco-
logic breast reconstruction is still emerging, with concerns about safety. The authors investigated the
dose-dependent interaction between human adipose-derived mesenchymal stromal cells (AD-MSCs) and
human breast cancer cell (BCC) lines [MDA-MB-231 (MDA) and MCF-7 (MCF)] focusing on tumor
microenvironment, tumor growth, and metastatic spread. METHODS: Adipose-derived mesenchymal
stromal cell influence on viability and factor expression [regulated on activation, normal T cell expressed
and secreted (RANTES), tumor necrosis factor-￿, and eotaxin) of breast cancer cells was studied in
vitro using direct and indirect co-culture systems. Groups were formed according to adipose-derived
mesenchymal stromal cell-to-cancer cell number ratio [MDA/MCF only, AD-MSC/(MDA/MCF), and
AD-MSC/(MDA/MCF)]. A humanized orthotopic murine cancer model was used to evaluate breast can-
cer progression and metastasis (n = 10/group). Cells were injected into the mammary pad in different
ratios and animals were monitored over 42 days. Microdialysis was performed to analyze RANTES levels
in the tumor microenvironment (days 21 and 42). Primary and metastatic tumors were weighed and
analyzed for oncogene, growth factor, and metastatic marker expression. RESULTS: MDA cell viability
increased from 45.5 percent to 95.5 percent in presence of adipose-derived mesenchymal stromal cells in
vitro. In vivo, animals with AD-MSC showed increased mean tumor weight (MDA, p < 0.01; MCF versus
controls, p < 0.05) and metastatic occurrence (40 percent in MDA; 30 percent in MCF versus 0 percent
in controls). Cytokine analysis revealed switching of MCF tumor phenotype to a more malignant type
in the presence of adipose-derived mesenchymal stromal cells. CONCLUSION: Human adipose-derived
mesenchymal stromal cells may promote progression and metastatic spread in breast cancer through a
switch to a more malignant phenotype with worse prognosis.
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The breast has a high cellular turnover for gland renewal under hormonal influence, with stem cells differentiating into ductal, 
alveolar, and myoepithelial cells.1,2 This highly 
active environment is prone to the risk of failure, 
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Background: Stem cell–enriched fat grafting has been proposed as a potential 
therapy for reconstructive, restorative, or enhancement-related procedures of 
the breast. Its role in postoncologic breast reconstruction is still emerging, with 
concerns about safety. The authors investigated the dose-dependent interaction 
between human adipose-derived mesenchymal stromal cells (AD-MSCs) and hu-
man breast cancer cell (BCC) lines [MDA-MB-231 (MDA) and MCF-7 (MCF)] 
focusing on tumor microenvironment, tumor growth, and metastatic spread.
Methods: Adipose-derived mesenchymal stromal cell influence on viability and 
factor expression [regulated on activation, normal T cell expressed and secreted 
(RANTES), tumor necrosis factor-α, and eotaxin) of breast cancer cells was stud-
ied in vitro using direct and indirect co-culture systems. Groups were formed 
according to adipose-derived mesenchymal stromal cell–to–cancer cell num-
ber ratio [MDA/MCF only, AD-MSClow/(MDA/MCF), and AD-MSChigh/(MDA/
MCF)]. A humanized orthotopic murine cancer model was used to evaluate 
breast cancer progression and metastasis (n = 10/group). Cells were injected 
into the mammary pad in different ratios and animals were monitored over 42 
days. Microdialysis was performed to analyze RANTES levels in the tumor mi-
croenvironment (days 21 and 42). Primary and metastatic tumors were weighed 
and analyzed for oncogene, growth factor, and metastatic marker expression.
Results: MDA cell viability increased from 45.5 percent to 95.5 percent in 
presence of adipose-derived mesenchymal stromal cells in vitro. In vivo, ani-
mals with AD-MSChigh showed increased mean tumor weight (MDA, p < 0.01; 
MCF versus controls, p < 0.05) and metastatic occurrence (40 percent in MDA; 
30 percent in MCF versus 0 percent in controls). Cytokine analysis revealed 
switching of MCF tumor phenotype to a more malignant type in the presence 
of adipose-derived mesenchymal stromal cells.
Conclusion: Human adipose-derived mesenchymal stromal cells may promote 
progression and metastatic spread in breast cancer through a switch to a more 
malignant phenotype with worse prognosis. (Plast. Reconstr. Surg. 136: 76, 2015.)
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making breast cancer the most frequent malig-
nancy in women today.
For reconstructive purposes, treatment with 
fat grafting has been suggested as an option for 
cancer patients.3,4 Fat grafting is also considered 
for aesthetic breast augmentation. However, 
despite extensive experience with fat grafting for 
scar treatment and as a filler, it is indeed not con-
sidered a reproducible and predictable technique. 
Moreover, safety guidelines for these procedures 
are currently based on recommendations derived 
from cancer biology, individual risk analysis, and 
basic science evidence.5 Newest approaches are 
based on the use of stem cell–enhanced fat graft-
ing for improved outcome, regardless of the lack 
of scientific evidence for the procedure’s safety.6,7 
Adult human mesenchymal stem cells are a suit-
able cell type and can be isolated from white 
adipose tissue, which makes adipose-derived mes-
enchymal stromal cells interesting because of ease 
of harvest. These cells have multiple functions, 
including the secretion of soluble factors through 
which they participate and contribute to immu-
nomodulation, antiapoptosis, angiogenesis, and 
regeneration.8–10 Because of these functionalities, 
local and migrating stem cells have been suspected 
to endorse breast cancer development.11,12 Sug-
gested by reports, adipose-derived mesenchymal 
stromal cells, and more in general mesenchymal 
stem cells, can promote progression and metasta-
sis of breast cancer13–17 through homing of stem 
cells to tumors as an evident process.18–20 Cyto-
kines and chemokines might play a role in breast 
cancer growth,21,22 metastasis, or recurrence, with 
growing evidence that growth and progression of 
breast tumors depend on their microenvironment 
as well.23,24 In this study, we investigated the inter-
actions of human breast cancer cells with human 
adipose-derived mesenchymal stromal cells more 
in detail, focusing on the influence of the adipose-
derived mesenchymal stromal cell–to–breast can-
cer cell ratio and its effects on cancer promotion 
and metastasis.
MATERIALS AND METHODS
Cell Cultures
Human adipose-derived mesenchymal stro-
mal cells were isolated from female abdominal 
lipoaspirates (postmenopausal, no family history of 
cancer, nonsmoking, nondiabetic) after informed 
consent and cantonal ethics committee approval. 
Adipose-derived mesenchymal stromal cells were 
isolated according to previously established pro-
tocols in our laboratory. Briefly, the lipoaspirates 
were digested in equal volume of mixture of 0.1% 
collagenase type I (Sigma-Aldrich, St. Louis, Mo.), 
1% bovine serum albumin (Sigma-Aldrich), and 
2 mM calcium chloride in phosphate-buffered 
saline; centrifuged; and resuspended in Dulbec-
co’s Modified Eagle Medium/F-12 (Invitrogen, 
Life Technologies Europe, Zug, Switzerland) sup-
plemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin (Gibco, Zug, Switzerland) 
for cell culture at 37°C with 5% carbon dioxide.
Flow cytometry was performed on adipose-
derived mesenchymal stromal cells (passage 2) 
for mesenchymal characterization. (See Figure, 
Supplemental Digital Content 1, which shows 
characterization of human adipose-derived mes-
enchymal stromal cells. Primary isolated human 
adipose-derived mesenchymal stromal cells were 
stained for CD34, CD73, CD90, and CD105 and 
characterized by fluorescence-activated cell sort-
ing. Bar graphs show mean ± SD, http://links.lww.
com/PRS/B319.)
The cancer cell lines MDA-MB-231 (MDA) and 
MCF-7 (MCF) were cultured in Dulbecco’s Modi-
fied Eagle Medium containing 10% fetal bovine 
serum. On confluence, cells were detached with 
trypsin (0.25%)/ethylenediaminetetraacetic acid 
(1 mM), counted with a hemocytometer with try-
pan blue exclusion, and aliquoted to the cell num-
ber required.
Co-culture Systems
Different adipose-derived mesenchymal stro-
mal cell–to–breast cancer cell ratios were used 
for co-cultures, seeding 5 × 104 adipose-derived 
mesenchymal stromal cells (AD-MSC) and differ-
ent amounts of breast cancer cells (BCC) per well: 
5 × 105 (AD-MSClow/BCC), 5 × 104 (AD-MSCequal/
BCC), and 5 × 103 (AD-MSChigh/BCC). Breast can-
cer cells and adipose-derived mesenchymal stro-
mal cells alone served as controls.
Indirect co-cultures were conducted in six-
well plates with transparent 3-µm-pore membrane 
inserts (ThinCert; Greiner Bio One, St. Gallen, 
Switzerland). Adipose-derived mesenchymal 
stromal cells were seeded into inserts and breast 
cancer cells in the bottom. Adipose-derived mes-
enchymal stromal cells and breast cancer cells 
were allowed to share the same media (Dulbecco’s 
Modified Eagle Medium/F-12, 10% fetal bovine 
serum, 1% penicillin/streptomycin) over 8 days. 
The percentage of viable breast cancer cells was 
analyzed by means of propidium iodide (0.1 µg/
ml) uptake using flow cytometry. Viability assay 
was performed only for MDA cells because of slow 
growth of MCF cells and no influence on viability.
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Similarly, direct co-cultures were conducted 
in six-well plates with adipose-derived mesenchy-
mal stromal cell/breast cancer cell mixtures as 
described above. Cells were cultured for 8 days 
and the supernatant was collected for single-run 
multiplex assay analysis.
Animal Model
Animal experiments were performed accord-
ing to national guidelines for the care and use of 
laboratory animals and with approval of the local 
animal ethics committee. Six-week-old nu/nu mice 
(Charles River, Sulzfeld, Germany) were injected 
with 2.5 × 106 MDA cells suspended in 100 µl of 
serum-free medium into the right fourth mammary 
pad. Two million (AD-MSChigh/MDA group, n = 
10) or 0.2 × 106 AD-MSC (AD-MSClow/MDA group, 
n = 10) were injected at the same site. As a con-
trol, one group was not injected with adipose-
derived mesenchymal stromal cells (MDA group, 
n = 10). Similarly, for the MCF groups, animals 
were injected with 0.5 × 106 MCF cells into the 
right fourth mammary pad coupled to 1 × 106 AD-
MSC (AD-MSChigh/MCF group, n = 10), 0.1 × 106 
AD-MSC (AD-MSClow/MCF group, n = 10), or no 
AD-MSC as a control (MCF group, n = 10). All ani-
mals were observed for 42 days, after which they 
were euthanized and inspected for tumors. Pri-
mary tumors at the injection site and abdominal 
metastases were harvested and weighed.
Microdialysis
Microdialysis was performed on days 21 and 42 
for regulated on activation, normal T cell expressed 
and secreted (RANTES) measurement in the tumor 
microenvironment (n = 3 per group). Anesthesia 
and antidote reversion were achieved using triple-
mix injections as described previously.9,10 Microdialy-
sis microprobes (CMA20, 100 kDa; Polyethersylfone; 
CMA Microdialysis, Stockholm, Sweden) were 
inserted into the peritumoral tissue and perfused 
with Ringer/hydroxyethyl starch 6% (Fresenius, 
Oberdorf, Switzerland) using a microinjection 
pump (CMA/100; Polyethersylfone). The perfu-
sion rate was set to 1 µl/minute as described previ-
ously.25,26 The probes were perfused for 30 minutes 
for equilibration before sample collection. Dialysates 
were stored at −80°C and analyzed for RANTES.
Multiplex Assays
Multiplex assays were performed on tumor 
lysates and dialysates. A cell lysis kit was used accord-
ing to the manufacturer’s instructions to obtain 
tumor lysates (Bio-Rad, Cressier, Switzerland). 
Human cytokine 27-plex kit and cancer panel I 
16-plex kit (M50-0KCAF0Y and 171-AC500M; Bio-
Rad) were used according to the manufacturer’s 
instructions to measure different markers.
Histologic Analysis
The tumors were fixed in 4% formaldehyde 
and embedded in paraffin. Four-micron sec-
tions were stained for hematoxylin and eosin and 
CD31 and CD90 (polyclonal antibodies; Lifespan 
Biosciences, Inc., Seattle, Wash.).27 For immuno-
fluorescence, secondary antibodies conjugated 
with fluorescent dyes (anti-rabbit Alexa 488; Life 
Technologies, Switzerland) and anti-goat Cy3 
(Millipore; Switzerland) were used. After sec-
ondary antibody incubation, sections were coun-
terstained with 4′,6-diamidino-2-phenylindole 
(Sigma-Aldrich, Buchs, Switzerland).
Statistical Analysis
GraphPad Prism (GraphPad Software, Inc., 
San Diego, Calif.) was used for statistical analysis. 
Nonparametric Kruskal-Wallis test with Dunn’s 
multiple comparison was performed to observe 
differences between the groups. Values of p < 0.05 
were chosen for statistical significance.
RESULTS
Co-Cultures
A higher adipose-derived mesenchymal stro-
mal cell–to-MDA ratio favored breast cancer cell 
survival through cytokine exchange over the per-
meable membrane in indirect co-cultures. (See 
Figure, Supplemental Digital Content 2, which 
shows indirect co-culture. MDA and adipose-
derived mesenchymal stromal cells were indi-
rectly co-cultured at different ratios and stained 
with propidium iodide to assess cell viability after 
8 days, http://links.lww.com/PRS/B320.) MDA cells 
cultured with AD-MSClow and AD-MSCequal were 
50.1 percent and 47.9 percent viable after 8 days, 
whereas in those cultured with AD-MSChigh, the 
MDA cell viability increased to 95.5 percent. In 
the absence of AD-MSC, MDA cells showed 54.5 
percent viability.
Supernatants from direct adipose-derived 
mesenchymal stromal cell/breast cancer cell 
co-cultures were assessed for RANTES, tumor 
necrosis factor (TNF)-α, and eotaxin. (See 
Figure, Supplemental Digital Content 3, which 
shows direct co-culture. Direct co-culture of adi-
pose-derived mesenchymal stromal cells with MDA 
or MCF cells was performed and supernatants 
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were tested for RANTES, TNF-α, and eotaxin 
expression, http://links.lww.com/PRS/B321.) An 
increasing AD-MSC/MDA ratio enhanced RAN-
TES expression (358 pg/ml, 242 pg/ml, and 
237 pg/ml for AD-MSChigh, AD-MSCequal, and 
AD-MSClow, respectively; 130 pg/ml for MDA). 
Increased RANTES expression was determined 
for decreasing AD-MSC/MCF ratios (28 , 170, and 
158 pg/ml for AD-MSChigh, AD-MSCequal, and AD-
MSClow, respectively; 47 pg/ml for MCF). RANTES 
expression for AD-MSC was 47 pg/ml.
TNF-α expression showed a trend similar to 
that for RANTES. It increased under AD-MSC 
influence for MDA (37 pg/ml for AD-MSChigh, 30 
pg/ml for AD-MSCequal, and AD-MSClow; 27 pg/ml 
for MDA) and decreased in MCF cultures, increas-
ing the AD-MSC dose (13, 24, and 21 pg/ml for 
AD-MSChigh, AD-MSCequal, and AD-MSClow, respec-
tively; and 8 pg/ml for MCF). TNF-α was 14 pg/ml 
for adipose-derived mesenchymal stromal cells.
Eotaxin was highly expressed in MDA cells 
with AD-MSChigh (81 pg/ml) and decreased with 
fewer adipose-derived mesenchymal stromal cells 
(27 and 31 pg/ml for AD-MSCequal and AD-MSClow, 
respectively; 38 pg/ml for MDA). For MCF cells, 
eotaxin was 14 pg/ml (AD-MSChigh), 20 pg/ml 
(AD-MSCequal), and 14 pg/ml (AD-MSClow), and 1 
pg/ml for MCF, whereas adipose-derived mesen-
chymal stromal cells exhibited the highest levels 
(97 pg/ml).
Tumor Progression
Primary and metastatic tumors were isolated 
and weighed on day 42 (Fig. 1). Adipose-derived 
mesenchymal stromal cells promoted larger 
tumors. MCF primary tumors had a volume of 
0.80 ± 1.79 mm3, whereas tumor volume was 7.79 ± 
9.27 mm3 for AD-MSClow (not significant) and 9.31 
± 5.76 mm3 for AD-MSChigh (p < 0.01 versus MCF). 
MDA tumors were 27 ± 56 mm3, 55 ± 82 mm3 with 
AD-MSClow, and 79 ± 182 mm3 with AD-MSChigh 
(not significant). Total tumor weight including 
primary tumor and metastases increased signifi-
cantly in MCF tumors with AD-MSChigh [20 ± 21 mg 
versus 4 ± 7 mg (MCF) and 5 ± 6 mg (AD-MSClow); 
p < 0.05]. MDA tumors were larger (68 ± 131 mg) 
and promoted by AD-MSClow and AD-MSChigh (179 
± 244 mg and 368 ± 491 mg; p < 0.01 versus MDA).
Besides increased progression, adipose-
derived mesenchymal stromal cells influenced 
cancer cells by increasing metastatic spread. Two 
mice from AD-MSChigh/MDA died prematurely 
(days 34 and 40) because of advanced metastatic 
disease. In MDA-only animals, no metastases were 
found. Conversely, 20 percent of the animals 
developed metastases with AD-MSClow, whereas 
occurrence increased to 40 percent with AD-
MSChigh. A similar metastatic behavior was found 
in MCF tumors, even though occurrence of metas-
tases was comparatively lower, being a low-malig-
nancy breast cancer cell line. Animals with MCF 
only and AD-MSClow had no metastases, whereas 
the rate increased to 30 percent with AD-MSChigh.
Tumor Lysates
Tumor samples were processed to determine 
the concentration of cancer and angiogenesis 
biomarkers. Each group consisted of 10 animals, 
Fig. 1. Tumor weight measurements and metastatic spread. Primary and metastatic tumors 
were measured in all animals after 6 weeks. Bar graph depicts the mean and SD of tumor 
size and indicates the percentage of metastatic tumor for each group. AD-MSC, adipose-
derived mesenchymal stromal cells.
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but not all in the breast cancer cell–only groups 
developed tumors; thus, the number of samples 
in these was reduced. In MDA animals, sHER-2/
neu levels were 1011 ± 202 pg/ml and decreased 
under adipose-derived mesenchymal stromal cell 
influence (732 ± 277 pg/ml and 619 ± 445 pg/ml 
for AD-MSChigh and AD-MSClow, respectively; not 
significant). [See Figure, Supplemental Digital 
Content 4, which shows cancer markers in tumor 
tissue samples. sHER2/neu (MDA and MCF), 
follistatin (MDA), and osteopontin (MDA) 
expression were determined in tumor lysates by 
multiplex assay. Each data point represents one 
animal. Statistical analysis was performed using 
the Kruskal-Wallis test with Dunn’s multiple com-
parison, http://links.lww.com/PRS/B322.] In MCF 
animals, sHER-2/neu was 62.04 ± 20 pg/ml and 
increased with adipose-derived mesenchymal stro-
mal cells to 515.8 ± 751 pg/ml (AD-MSChigh) and 
1335 ± 789 pg/ml (AD-MSClow; p < 0.05 versus MCF). 
(See Figure, Supplemental Digital Content 4, 
http://links.lww.com/PRS/B322.)
Follistatin in MDA animals showed a trend 
similar to that for sHER-2/neu, with no significant 
differences between the groups (484 ± 145 pg/
ml and 404 ± 217 pg/ml for AD-MSChigh and AD-
MSClow, respectively; 578 ± 42 pg/ml for MDA). 
(See Figure, Supplemental Digital Content 4, 
http://links.lww.com/PRS/B322.) In MCF animals, 
follistatin levels were 1687 ± 881 pg/ml and sig-
nificantly lower with adipose-derived mesenchy-
mal stromal cells (470.6 ± 274 and 434.3 ± 139 for 
AD-MSChigh and AD-MSClow, respectively; p < 0.05 
versus MCF) (Fig. 2).
Osteopontin levels were 1200 ± 22 pg/ml for 
MDA tumors (see Figure, Supplemental Digital 
Content 4, http://links.lww.com/PRS/B322) and 
decreased to 961.8 ± 214 pg/ml (AD-MSChigh) 
and 893.4 ± 365 pg/ml (AD-MSClow) with adipose-
derived mesenchymal stromal cells (not signifi-
cant); whereas in MCF-only tumors, osteopontin 
was significantly higher (2639 ± 1337 pg/ml) 
compared with AD-MSChigh and AD-MSClow (1177 
± 320 pg/ml and 1085 ± 144 pg/ml, respectively; 
p < 0.05 versus MCF) (Fig. 3).
Angiogenesis within the tumor microenviron-
ment was determined by analyzing tumor lysates 
for soluble Tie-2 (sTie-2) and platelet-derived 
growth factor (PDGF) AB/BB. (See Figure, 
Supplemental Digital Content 5, which shows 
tumor angiogenesis markers. sTie-2 and PDGF 
AB/BB levels in tumor lysates were determined by 
multiplex assay. Each data point represents one 
animal. Statistical analysis was performed using 
Kruskal-Wallis test with Dunn’s multiple compari-
son, http://links.lww.com/PRS/B323.) sTie-2 levels 
showed significant differences between MDA and 
MCF animals depending on adipose-derived mes-
enchymal stromal cell dosage. Adipose-derived 
mesenchymal stromal cells diminished sTie-2 
levels in MDA tumors (587 ± 109 pg/ml and 
407 ± 145 pg/ml for AD-MSChigh and AD-MSClow, 
respectively; 723 ± 23 pg/ml for MDA; p < 0.05 
versus MDA). MCF animals (1800 ± 865 pg/ml) 
had significantly higher levels than AD-MSC/
MCF animals (507 ± 178 and 460 ± 115 pg/ml for 
AD-MSChigh and AD-MSClow, respectively; p < 0.05 
versus MCF). PDGF AB/BB values were not differ-
ent between the MDA groups (209 ± 78 and 211 ± 
Fig. 2. Follistatin expression in MCF tumors. Follistatin expression was determined in tumor 
lysates by multiplex assay. Each data point represents one animal. Statistical analysis per-
formed using Kruskal-Wallis test with Dunn’s multiple comparison.
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166 pg/ml for AD-MSChigh and AD-MSClow, respec-
tively; 262 ± 2 g/ml for MDA). MCF tumors had 
1248 ± 959 pg/ml PDGF AB/B, which decreased 
significantly with AD-MSCs (221 ± 149 and 186 ± 
52 pg/ml for AD-MSChigh and AD-MSClow, respec-
tively; p < 0.05 versus MCF).
Tumor Dialysates
Dialysates from the tumor microenvironment 
were assessed for RANTES to account for tumor 
invasion potential. (See Figure, Supplemental 
Digital Content 6, which shows the tumor micro-
environment. Samples from the tumor microen-
vironment were collected on days 21 and 42 to 
determine expression of RANTES. Bar graphs 
represent mean and SD, http://links.lww.com/PRS/
B324.) Results are grouped as AD-MSC/MDA and 
AD-MSC/MCF, without distinction between ratios. 
For animals injected with MDA cells only, levels 
were maintained over time (8 ± 2 pg/ml on day 
21 and 7 ± 1 pg/ml on day 42). RANTES expres-
sion was 7 ± 0 and 6 ± 1 pg/ml, respectely, for MCF 
tumor. In animals receiving adipose-derived mes-
enchymal stromal cells, RANTES expression was 
increased in both breast cancer cell lines (10 ± 4 
and 9 ± 1 pg/ml for AD-MSC/MDA; and 9 ± 1 and 
8 ± 1 pg/ml for AD-MSC/MCF).
Histologic Analysis 
Hematoxylin and eosin–stained tumor sections 
revealed a heterogeneous distribution of different 
cell types and clusters in the nodules. [See Fig-
ure, Supplemental Digital Content 7, which shows 
Immunostaining of tumor tissue samples. Samples 
from the tumor were fixed in paraffin and stained 
as described earlier under Materials and Methods. 
Hematoxylin and eosin staining of tumor node 
(above, left), CD31 staining in an animal injected 
with MDA only (above, right) and in one injected 
with MDA and adipose-derived mesenchymal stro-
mal cells (below). Scale bar = 40 µm, http://links.lww.
com/PRS/B325.] There was a relatively clear mar-
gin zone at the interface between human cancer 
and mouse subdermal tissue, and no difference was 
observed between the different groups. Samples 
from animals that were injected with MDA cells 
showed CD31 positivity confined along the vascu-
lature (see Figure, Supplemental Digital Content 7, 
above, right, http://links.lww.com/PRS/B325). In con-
trast, when adipose-derived mesenchymal stromal 
cells were combined with MDA, single large mono-
nuclear CD31+ cells were found in tissue other than 
vessels (see Figure, Supplemental Digital Content 7, 
below, http://links.lww.com/PRS/B325). To evaluate 
whether the infiltrating CD31+ cells were differen-
tiated adipose-derived mesenchymal stromal cells, 
samples were double-stained with CD90 antibody, 
which revealed no overlapping cells, suggesting the 
infiltrated CD31+ cells were not differentiated stem 
cells (Fig. 4). Indeed, single CD90+ cells were found 
in proximity to blood vessels or the previously men-
tioned CD31+ cells.
DISCUSSION
Our study highlights the influence of adipose-
derived mesenchymal stromal cells on phenotypic 
and metastatic characteristics of breast cancer 
cells and confirms that adipose-derived mesenchy-
mal stromal cells predispose tumor cells toward 
growth, metastasis, and dedifferentiation. Our 
Fig. 3. Osteopontin expression in MCF tumors. Osteopontin expression was determined in 
tumor lysates by multiplex assay. Each data point represents one animal. Statistical analysis 
was performed using Kruskal-Wallis test with Dunn’s multiple comparison.
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study also establishes the effects of varying con-
centrations of adipose-derived mesenchymal stro-
mal cells on breast cancer cells both in vitro and 
in vivo. A high adipose-derived mesenchymal stro-
mal cell–to–breast cancer cell ratio revealed a sig-
nificant increase in cancer cell viability for MDA 
in vitro. This demonstrates that increasing the 
adipose-derived mesenchymal stromal cell dose 
may stimulate even minimal numbers of residual 
breast cancer cells. These data underscore the 
potential risk of adipose-derived mesenchymal 
stromal cell–based strategies in postoncologic 
breast reconstruction, especially because micro-
scopic tumor cell pockets may remain after the 
most thorough tumor resection. Self-limiting can-
cer cell death was turned off in MDA cells by a 
suggestive paracrine influence of adipose-derived 
mesenchymal stromal cells in our indirect co-cul-
ture system.
Adipose-derived mesenchymal stromal cells 
influenced tumor progression and metastasis 
formation, depending on the breast cancer cell 
type. Adipose-derived mesenchymal stromal cells 
not only activated the breast cancer cells but 
also stimulated a more aggressive and prolifera-
tive phenotype. Indeed, a phenotypic switch was 
observed in vivo in both MDA and MCF cell lines, 
resulting in increased tumor progression and 
metastatic spread. The MCF cell line switched 
from a nonmetastasizing to a metastasizing phe-
notype with similar expression profiles for HER2/
neu, follistatin, and osteopontin as for the MDA 
cell type. The latter two markers are predictive of 
malignant potential and are associated with poor 
prognosis and higher rates of metastatic spread 
and recurrence in patients. Our results confirm 
previous reports of murine CD34+ cells and adi-
pose-derived mesenchymal stromal cells enhanc-
ing growth and progression of different murine 
and human breast cancer cell lines.17,28 Earlier, 
other authors used CD34+ progenitors from adi-
pose tissue,29 mesenchymal stem cells from other 
sources,30 or nonhuman cells.17,28 Recently, Rowan 
et al. found significantly increased multiorgan 
spreading of MDA tumors and partial epithelial-
to-mesenchymal transition after local addition 
of human adipose-derived mesenchymal stromal 
cells; however, in contrast to earlier reports, they 
found no increase of breast cancer cell growth.16 
In our study, we could demonstrate dose-depen-
dent effects, which may have a high impact on the 
clinical scenario.
Adipose-derived mesenchymal stromal cells 
did not alter HER2/neu expression and down-
regulation of follistatin and osteopontin in MDA 
cells, as these were already expressed or down-reg-
ulated in the more aggressive MDA cell line. In 
agreement with our findings, others have reported 
NCOA4, FOS oncogene up-regulation, and IGF-
1R– and BCL2-related antiapoptotic effects.31
However, adipose-derived mesenchymal stro-
mal cells in co-cultures with breast cancer cells led 
to increased levels of TNF-α, RANTES, and eotaxin 
expression, which can be correlated to higher 
migratory and metastatic potential. This was veri-
fied in vivo by microdialysis. Ahmad et al. described 
the importance of the microenvironmental influ-
ence of adipose-derived mesenchymal stromal 
cells, including nuclear factor kappa β regulation 
of angiogenesis and invasion,32 whereas Chaturvedi 
et al. could show a hypoxia inducible factor-1α–
dependent potential of mesenchymal stem cells 
to promote breast cancer progression and metas-
tasis33 as reflected by SDF-1/CXCR4 regulation.17,34
Although adipose-derived mesenchymal stro-
mal cells have been shown to have high regenerative 
potential and express high levels of vascular growth 
factors, we observed down-regulation of PDGF and 
Tie-2 in cancer tissue samples. Even though solid 
tumors and metastases developed (which depends 
on sufficient vascularity), interestingly, these vas-
cular factors were not supportively up-regulated. 
That mesenchymal stem cells may also have anti-
angiogenic effects on cancer has been shown previ-
ously.35,36 Surprisingly, our results for PDGF-D are 
contrary to the current literature, because PDGF-D 
expression of breast cancer cells has been associ-
ated with aggressive cancer biology.22,32 We believe 
that this may be attributable to the large tumor 
mass, and PDGF might be expressed to a higher 
Fig. 4. Immunostaining of tumor tissue samples. Sample from 
an animal injected with MDA and AD-MSC, double-stained for 
CD31 and CD90. Single CD90+ cells (red) were found in proximity 
to CD31+ cells (green).
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extent in the transition zone, where cancer angio-
genesis would be most needed to feed the grow-
ing mass. Another group detected antiangiogenic 
effects of mesenchymal stem cells in high local con-
centration, which resulted in tumor cell apoptosis 
and abrogated tumor progression.36 These results 
would be in line with our antivascular regulation as 
found for Tie-2 and PDGF.
Our study is the first to take advantage of pri-
mary human adipose-derived mesenchymal stro-
mal cells. Others have used CD34+ progenitors 
from adipose tissue,29 mesenchymal stem cells from 
other sources,30 or nonhuman cells previously. Fur-
thermore, our approach is unique in the way that 
it shows results being dependent on the adipose-
derived mesenchymal stromal cell–to–breast cancer 
cell ratio. Mesenchymal stem cells have been investi-
gated previously demonstrating promotion of breast 
cancer growth and cell viability in vivo and in vitro37 
in relation to the cytokine and growth factor expres-
sion modulating the cancer microenvironment as 
reported by Karnoub et al. and Kidd et al.38,39
Our findings are worrisome, as the rationale 
behind our study was to investigate the early 
events surrounding the cellular, cytokine, onco-
gene, or growth factor mediators that trigger or 
promote growth, dedifferentiation, or spread of 
breast cancer cells under the influence of differ-
ent adipose-derived mesenchymal stromal cell 
ratios. Our experimental data may also support 
the significant clinical findings by Petit et al. for 
higher recurrence in intraepithelial breast cancer 
patients after autologous fat grafting following 
breast-conserving surgery.40
Alharbi et al. reported a case of aggressive 
breast cancer recurrence 2 years after autolo-
gous fat grafting, with eventual spread to lungs 
and brain.41 However, the causal link between the 
events remains speculative.
Limitations of our study include the use of a 
humanized murine model, which might not depict 
the human tumor microenvironment closely 
enough. Furthermore, primary human breast can-
cer cells and adipose-derived mesenchymal stromal 
cells from the same patient would better represent 
the clinical scenario. The promoting effects found 
here are not necessarily mesenchymal stem cell–
specific and could potentially extend to additional 
cell types (e.g., fibroblasts). Donor biology can also 
influence the results in a relevant manner.16
CONCLUSIONS
Our data suggest that adipose-derived mesen-
chymal stromal cells bear potential to promote 
tumor progression in breast cancer cell lines. This 
was demonstrated by increased breast cancer cell 
viability, tumor growth, and metastasis, in addi-
tion to oncogene up-regulation in the presence of 
adipose-derived mesenchymal stromal cells. How-
ever, our data also show decreased expression of 
the angiogenic factors Tie-2 and PDGF under the 
influence of adipose-derived mesenchymal stro-
mal cells. Under the line, promotion of breast 
cancer might depend on the cancer cell type and 
their ratio to adipose-derived mesenchymal stro-
mal cells. Reconstructive efforts with stem cell–
enhanced fat grafting may therefore require strict 
guidelines to ensure a cancer cell-free environ-
ment. There may be a narrow physiologic window 
regarding factor concentration in the complex 
interplay between adipose-derived mesenchy-
mal stromal cells and breast cancer cells. Further 
experimental and clinical research is required to 
determine the critical concentration of adipose-
derived mesenchymal stromal cells in relation to 
the type and stage of cancer to prevent progres-
sion or recurrence of breast cancer.
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